Brought to you by 
Esperion Therapeutics nets $74.9mm with its second IPO
02 Aug 2013
Executive Summary
Cardiometabolic drug developer Esperion Therapeutics Inc. has netted $74.9mm through its initial public offering of 5.75mm common shares (including the overallotment) at $14, the midpoint of its proposed $13-15 range. Certain existing shareholders and affiliated entities bought a total of 1.2mm of the shares.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Esperion Therapeutics nets $74.9mm with its second IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice